Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Current Liabilities (2016 - 2025)

Northwest Biotherapeutics' Total Current Liabilities history spans 16 years, with the latest figure at $91.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $91.7 million for Q4 2025, up 34.31% from a year ago — trailing twelve months through Dec 2025 was $91.7 million (up 34.31% YoY), and the annual figure for FY2025 was $91.7 million, up 34.31%.
  • Total Current Liabilities for Q4 2025 was $91.7 million at Northwest Biotherapeutics, up from $87.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $363.4 million in Q1 2021 to a low of $4.9 million in Q3 2023.
  • The 5-year median for Total Current Liabilities is $85.9 million (2025), against an average of $118.4 million.
  • The sharpest move saw Total Current Liabilities plummeted 95.74% in 2023, then skyrocketed 1105.26% in 2024.
  • Year by year, Total Current Liabilities stood at $133.8 million in 2021, then decreased by 5.8% to $126.0 million in 2022, then crashed by 64.13% to $45.2 million in 2023, then skyrocketed by 51.04% to $68.3 million in 2024, then skyrocketed by 34.31% to $91.7 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $91.7 million, $87.9 million, and $83.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.